Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), in-line with the analyst estimate of ($0.05). Revenue for the quarter came in at $700 thousand versus the consensus estimate of $120 thousand.

Progress in Clinical Pipeline

• LX4211: Lexicon announced a collaboration with JDRF to support a Phase 2, randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy and safety of LX4211 in individuals with type 1 diabetes that are younger than 30 years of age. The study will be conducted with the primary objective being to evaluate the safety and effectiveness of LX4211 versus placebo as an adjunct to insulin treatment, as measured by HbA1c reduction at 12 weeks, as well as several secondary endpoints.
• Telotristat etiprate (LX1032): Lexicon continues to make progress in the enrollment of carcinoid syndrome patients in a pivotal Phase 3 clinical trial of telotristat etiprate, an inhibitor of tryptophan hydroxylase (TPH) that reduces peripheral serotonin production without affecting brain serotonin levels.

For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.